Patents by Inventor Marius Hoener
Marius Hoener has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240085402Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.Type: ApplicationFiled: October 20, 2023Publication date: March 14, 2024Inventors: Veronica COSTA, Maj HEDTJÄRN, Marius HOENER, Ravi JAGASIA, Mads Aaboe JENSEN, Christoph PATSCH, Lykke PEDERSEN, Søren Vestergaard RASMUSSEN
-
Patent number: 11852627Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.Type: GrantFiled: January 21, 2022Date of Patent: December 26, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
-
Publication number: 20230296587Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD1091B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.Type: ApplicationFiled: February 22, 2023Publication date: September 21, 2023Inventors: Veronica COSTA, Maj HEDTJÄRN, Marius HOENER, Ravi JAGASIA, Mads Aaboe JENSEN, Christoph PATSCH, Lykke PEDERSEN, Søren Vestergaard RASMUSSEN
-
Publication number: 20220146496Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.Type: ApplicationFiled: January 21, 2022Publication date: May 12, 2022Inventors: Veronica Costa, Maj HEDTJÄRN, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
-
Patent number: 11320421Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.Type: GrantFiled: July 20, 2020Date of Patent: May 3, 2022Assignee: Hoffmann-La Roche Inc.Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
-
Patent number: 11312711Abstract: The present invention relates to a compound of formula and to a pharmaceutically suitable acid addition salt thereof with a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1, for the treatment of certain CNS diseases.Type: GrantFiled: June 11, 2020Date of Patent: April 26, 2022Assignee: Hoffmann-La Roche Inc.Inventors: Guido Galley, Marius Hoener, Roger Norcross, Philippe Pflieger
-
Publication number: 20210122743Abstract: The present invention relates to a compound of formula and to a pharmaceutically suitable acid addition salt thereof with a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1, for the treatment of certain CNS diseases.Type: ApplicationFiled: June 11, 2020Publication date: April 29, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Guido GALLEY, Marius HOENER, Roger NORCROSS, Philippe PFLIEGER
-
Publication number: 20200348286Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.Type: ApplicationFiled: July 20, 2020Publication date: November 5, 2020Inventors: Veronica Costa, Maj HEDTJÄRN, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
-
Patent number: 10739332Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.Type: GrantFiled: April 18, 2019Date of Patent: August 11, 2020Assignee: Hoffmann-La Roche Inc.Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
-
Patent number: 10718753Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.Type: GrantFiled: October 24, 2019Date of Patent: July 21, 2020Assignee: Hoffman-La Roche Inc.Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
-
Patent number: 10577332Abstract: The present invention relates to compounds of formula I wherein R1? is CH3 R1 is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1? and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, methyl, ethyl, isopropyl, tertbutyl, cyclopropyl or CF3; R3 is Cl, F, CF3, methyl, methoxy, isopropyl or cyclopropyl; R4 is hydrogen, methyl, F or Cl; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof for use in the treatment of schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.Type: GrantFiled: April 19, 2016Date of Patent: March 3, 2020Assignee: Hoffmann-La Roche Inc.Inventors: Marius Hoener, Juergen Wichmann
-
Publication number: 20200057052Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.Type: ApplicationFiled: October 24, 2019Publication date: February 20, 2020Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
-
Patent number: 10556870Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R1?, R2, R3, R4 are as defined herein, compositions including the compounds and methods of using the compounds.Type: GrantFiled: April 12, 2019Date of Patent: February 11, 2020Assignee: Hoffmann-La Roche Inc.Inventors: Marius Hoener, Juergen Wichmann
-
Patent number: 10508107Abstract: The present invention relates to a compound of formula and to a pharmaceutically suitable acid addition salt thereof with a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1, for the treatment of certain CNS diseases.Type: GrantFiled: September 13, 2018Date of Patent: December 17, 2019Assignee: Hoffmann-La Roche Inc.Inventors: Guido Galley, Marius Hoener, Roger Norcross, Philippe Pflieger
-
Patent number: 10494633Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.Type: GrantFiled: November 14, 2016Date of Patent: December 3, 2019Assignee: Roche Innovation Center Copenhagen A/SInventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
-
Patent number: 10457644Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R1?, R2, R3, R4 are as defined herein, compositions including the compounds and methods of using the compounds.Type: GrantFiled: November 19, 2018Date of Patent: October 29, 2019Assignee: Hoffman-La Roche Inc.Inventors: Marius Hoener, Juergen Wichmann
-
Patent number: 10457663Abstract: The present invention relates to compounds of formula I wherein R1? is CH3; R1 is CH3, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1? and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, CH3, ethyl, isopropyl, tert-butyl, cyclopropyl, cyclopropyl-methyl or hydroxy-methyl; R3 is hydrogen, Cl, F, CF3, CH3, isopropyl, methoxy, cyano or cyclopropyl; R4 is hydrogen, CH3, F or Cl; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.Type: GrantFiled: July 30, 2018Date of Patent: October 29, 2019Assignee: Hoffmann-La Roche Inc.Inventors: Marius Hoener, Juergen Wichmann
-
Publication number: 20190310244Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.Type: ApplicationFiled: April 18, 2019Publication date: October 10, 2019Inventors: Veronica Costa, Maj HEDTJÄRN, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
-
Publication number: 20190233379Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R1?, R2, R3, R4 are as defined herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: April 12, 2019Publication date: August 1, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Marius HOENER, Juergen WICHMANN
-
Publication number: 20190154664Abstract: This patent application relates to a method for determining the in vitro efficacy profile of a drug candidate using standardized cell cultures of uniformly distributed differentiated neural cells (NCs) from at least two primate species, wherein the differentiated NC cultures are qualified for high throughput screening based on a dissociation and reseeding step performed on the differentiated NCs. The method includes differentiating human and/or non-human primate neuronal precursor cells (NPCs) to neuronal cells (NCs) followed by dissociating the differentiated NCs from its support and reseeding the differentiated NCs in a high-throughput cell culture format resulting in robust cultures suitable for high-throughput drug screening assays, in particular to screen antisense oligonucleotides.Type: ApplicationFiled: May 11, 2018Publication date: May 23, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Carlo CUSULIN, Veronica COSTA, Marius HOENER, Christoph PATSCH, Eva Christina THOMA